Skip to main content

Новости и события

eSRS symposium

Register for the eSRS Satellite Symposium : From new tracers developments to routine clinical applications on Synthera® + platform

PET modality is one of the most rapidly growing area of medical imaging thanks to the availability of innumerous clinical centers with their own cyclotrons. To be able to cover the growing clinical demands, radiopharmacies are developing new tracers while keeping up their routine production in a (c)GMP environment.  In this symposium, Dr. Ida Nymann Petersen, PhD. and Dr. Vasko Kramer, PhD.will share their experience in the development of new tracers on the Synthera® Platform.  When?  May 20th 4-5pm CET (Central European Time)   REGISTER What will you learn ?   Synthesis of [18F]mFBG and [18F]FE-PE2I on Synthera®+ platform By Dr. Ida Nymann Petersen, PhD., Radiochemist at Rigshospitalet in Copenhagen, Denmark.   In this talk, the fully automated labelling of [18F]mFBG and [18F]FE-PE2I on the Synthera®+ and Synthera®+ HPLC platform will be presented. [18F]FE-PE2I was synthesized in 32 % RCY, 98 % RCP in 40 min. [18F]mFBG is currently under optimization.    Development of new tracers: from neurology to oncology applications. By Dr. Vasko Kramer, PhD., Head of Research & Development at Positron Pharma in Santiago, Chile.  He will present some of their results for the production and development of new, innovative PET imaging agents for neurological ([18F]F-PR04.MZ, [18F]F-Florbetaben, [18F]F-PI-2620), oncological ([18F]FAPi-74, [18F]F-AlF-NOTA-Octreotide), and research applications (7-[18F]F-Fluoro-tryptophan, 18F-Tetrazines) using a compact, cassette-based synthesis platform.     You can join this symposium even if you don’t attend eSRS meeting.
Читать далее
SBRT and PSMA

Watch the webinar: The Role of Specific PET PSMA imaging and SBRT in the Management of Prostate Cancer

Thank you  Dr. Jeremie Calais, Dr. Stefan Korber and Dr. Kai Schubert for your instructive presentations!  Did you miss the webinar? Watch the recording In addition to all questions answered at the end of this webinar, here are a few remaining ones, which the speakers kindly answered: Do you think that PET imaging in treatment position needs to be done systematically (in order to decrease irradiation dose exposure) ? Dr Calais: No. This is not like head and Neck or lung. Rectal and bladder filling are too complex to really have exact repositioning from PSMA PET to treatment table. Dr Schubert: Treatment position is not absolutely necessary, of course favorable. Different positions between treatment planning CT and ‘diagnostic’ imaging can be taken care of by deformable image registration, but there are limitations and additional QA would be necessary.   Is there any comparison between PSMA-Targeted therapy and SBRT?  Dr Calais :  No (not yet). Trials of PSMA MRT for oligometastatic disease are underway. My personal opinion is that it may not be the best application as a single agent therapy because the local control is inferior than with SBRT. However it can treat the microscopic and small lesions, so maybe the combination of both is probably a good approach.   When should we re-image after PSMA guided MDT? after changes in PSA? Dr Calais : At least 4 months after the end of SBRT ( for the local control).Otherwise if suspicion of new lesions based on PSA rise after NADIR or other imaging suspicion or clinical symptom. Dr Korber: I think, checking the PSA is adequate. Sure, if the PSA is rising again, new imaging (e.g. another PSMA-PET/CT) should be evaluated.
Читать далее

О нас

Опираясь на 35-летний опыт, IBA RadioPharma Solutions помогает центрам ядерной медицины проектировать, строить и эксплуатировать отделения ПЭТ для производства радиофармпрепаратов, используемых для диагностики и лечения рака и других критических заболеваний.

IBA будут работать с вами и поддерживать в течение всего процесса — на первой встрече, при проектировании, монтаже и введении в эксплуатацию. Более того, эксперты IBA будут сопровождать вас на протяжении всего срока службы радиофармацевтического оборудования: проводить обучение, выполнять необходимые обновления и техническое обслуживание, чтобы обеспечить успех вашего проекта в соответствии с принципами устойчивого развития.

Читать далее
Who we are

Основные факты

до <strong>30 </strong>Ки

За один производственный цикл.

Для производства ФДГ.

до <strong>3</strong>

Модулей синтеза в одной горячей камере.

Мультипроизводство нескольких РФП

<strong>500</strong> +

модулей радиохимического синтеза Synthera® установлены в разных странах мира.

<strong>300</strong> +

циклотронов эксплуатируются и обслуживаются на 5 континентах.